Key Financial Metrics:

1. Reported revenue of $806.1 million, representing a 12.4% growth on a reported basis or 13.1% in constant currency.
2. Non-GAAP earnings per share of $0.50, which exceeded the forecast and showed a decline of 2.0% compared to the prior-year period.
3. Core revenues, excluding blood screening and Cynosure, grew 2.4% on a reported basis or 3.1% in constant currency.
4. Core EPS, excluding blood and Cynosure, would have increased by 11.9%.
5. Global sales of molecular diagnostics grew by a healthy 10.3%, with a high-single-digit growth rate in the United States and more than 20% growth internationally.
6. Cynosure posted revenue of $110 million, in line with quarterly guidance, with an increase in international sales and a low-teens growth rate in consumables sales.
7. Global Breast Health sales of $283.7 million increased by a modest 0.9% in constant currency, with a decline in the U.S. and an increase in international sales of 13%.
8. Service revenue from Breast Health exceeded $100 million.
9. Sales of new products exceeded $40 million globally, with expectations for continued growth in new products, including Brevera and new mammography systems.
10. Expectations for growth in 2018 for Cynosure, as well as reacceleration of overall company performance.